Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV

By: Benzinga
Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22nd
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.